The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection

Journal of Clinical Pharmacology

Volumn 48, Issue 4, 2008, Pages 512-517

  Sokal, Etienne M ^a   Kelly, Deirdre ^b   Wirth, Stefan ^c   Mizerski, Jacob ^d   Dhawan, Anil ^e   Frederick, David ^f  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF WITTEN HERDECKE   (Germany)

^d Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f GILEAD SCIENCES   (United States)

Author keywords

Adefovir dipivoxil; Adolescent; Chronic hepatitis B; Pediatric; Pharmacokinetics

Indexed keywords

ADEFOVIR DIPIVOXIL;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HUMAN; MALE;

ADENINE; ADOLESCENT; ANTIVIRAL AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HEPATITIS B, CHRONIC; HUMANS; MALE; PHOSPHONIC ACIDS;

EID: 40749119775     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007313325     Document Type: Article

References (10)

1. Sokal EM, Bortolotti F. Update on prevention and treatment of viral hepatitis in children. Curr Opin Pediatr. 1999 ; 11: 384-389.
2. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002 ; 347: 168-174.
3. Vo Thi DH, Bourgois A., Bontems P., et al. Chronic hepatitis B infection: long term comparison of children receiving interferon alpha and untreated controls. J Pediatr Gastroenterol Nutr. 2005 ; 40: 141-145.
4. Comanor L., Minor J., Conjeevaram HS, et al. Impact of chronic hepatitis B and interferon-alpha therapy on growth of children. J Viral Hepat. 2001 ; 8: 139-147.
5. Sokal EM, Wirth S., Goyens P., Depreterre A., Cornu C. Interferon alfa-2b therapy in children with chronic hepatitis B. Gut. 1993 ; 34: S87 - S90.
6. Jonas MM, Kelly DA, Mizerski J., et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med. 2002 ; 346: 1706-1713.
7. Sokal EM, Kelly DA, Mizerski J., et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology. 2006 ; 43: 225-232.
8. Marcellin P., Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003 ; 348: 808-816.
9. Dando MT, Plosker GL Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs. 2003 ; 63: 2215-2234.
10. Sokal EM, Roberts EA, Mieli-Vergani G., et al. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemother. 2000 ; 44: 590-597.